# BPC-157 TB-500 FAQ: The Wolverine Blend, Answered from the Record > BPC-157 TB-500 questions answered from the research and regulatory record — mechanism, synergy, tendon and muscle evidence, FDA 503A status, and WADA. Direct answers, cited. Definitional, mechanistic, efficacy, safety, and regulatory questions about the Wolverine blend — each answered directly and cited to the literature or the FDA record. ## Definitional ### What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide (`Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val`) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (`Ac-LKKTETQ`) corresponding to residues 17-23 of Thymosin Beta-4 [3]. The Wolverine blend pairs the two. Neither is an FDA-approved drug. ### What is the Wolverine peptide blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated. Most TB-500 efficacy data come from full-length Thymosin Beta-4 [4]. ### What is the BPC-157 and TB-500 blend used for in research? In animal models the two constituents are studied separately for tissue repair: BPC-157 for tendon, ligament, and muscle healing [1]; TB-500 / Thymosin Beta-4 for cell migration, wound re-epithelialization, and angiogenesis [4]. The combination itself has no controlled study [8]. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid pentadecapeptide (`~1419.5 Da`) from a human gastric-juice protein, acting on VEGFR2/eNOS angiogenic and growth-hormone-receptor pathways [2]. TB-500 is a 7-amino-acid acetylated fragment (`Ac-LKKTETQ`, `~889 Da`) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration [3]. ## Mechanism ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) [2] while TB-500 supplies an intracellular actin-sequestration signal driving cell migration [3]. The synergy is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study [8]. ### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? In research models, yes — by distinct routes. BPC-157 up-regulates VEGFR2 and promotes its internalization, with downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and speeding blood-flow recovery in ischemic muscle [2]. Thymosin Beta-4 promotes angiogenesis via endothelial migration, including restoring angiogenesis in aged animals [6]. ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500's `LKKTETQ` motif binds monomeric G-actin 1:1. X-ray crystallography of a gelsolin-domain-1-Thymosin-Beta-4 hybrid bound to actin established that Thymosin Beta-4 sequesters the actin monomer by capping both ends, preventing polymerization [3] — the cytoskeletal basis for its cell-migration role. ### How does BPC-157 work compared to TB-500? They act through largely non-overlapping pathways. BPC-157 is a local cytoprotective and pro-angiogenic signal (VEGFR2 up-regulation, then Akt, then eNOS) [2] while TB-500 is an intracellular actin-sequestration signal (G-actin binding via `LKKTETQ`) regulating cytoskeletal dynamics and migration [3]. ## Evidence and efficacy ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 (`36 studies`, only `1 human`) makes no mention of TB-500 or combination use; the synergy claim is an extrapolation [8]. ### Are there human clinical trials on the BPC-157 + TB-500 combination? No. There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies [10], and TB-500 human data are for full-length Thymosin Beta-4, not the heptapeptide. Recent reviews call BPC-157 investigational [10]. ### Does the BPC-157 TB-500 blend help tendon and ligament injuries? The evidence is animal-model and single-compound. BPC-157 accelerated healing of a transected rat Achilles tendon across biomechanical, functional, and microscopic measures, and stimulated tendocyte growth in vitro [1]; Thymosin Beta-4 enhanced ligament healing in animal models [4]. No human or combination tendon trial exists [8]. ### Does BPC-157 and TB-500 help muscle tears and recovery? Only in animal models, separately. BPC-157's tendon and tendocyte data [1] and Thymosin Beta-4's migration and cell-mobilization activity [4] are the basis of the recovery rationale. Human combination recovery data do not exist [9]. ### Does the BPC-157 TB-500 blend help wound healing? In animal models, the TB-500 side has wound-healing support: Thymosin Beta-4 promoted angiogenesis, wound healing, and hair-follicle development in normal and aged rodents [6], and the consolidated review describes re-epithelialization and reduced scar-forming myofibroblasts [4]. These are single-compound animal findings. ### How long does it take BPC-157 and TB-500 to work for an injury? No human timeline exists for the blend. The underlying evidence is animal-model: BPC-157 accelerated tendon healing across multiple measures in rats [1], but rodent recovery timelines do not translate to validated human expectations, and recent reviews treat both constituents as investigational [10]. ## Safety and regulatory ### Is TB-500 bad for your heart? There is no human cardiac-safety data for the TB-500 heptapeptide. BPC-157 has been reported to modulate vasomotor tone via the Src-Caveolin-1-eNOS pathway in animal and endothelial models [5], and 2025-2026 reviews stress that human safety data for both constituents are scarce and that both remain investigational [9] [10]. ### What are the side effects of BPC-157 and TB-500? There is no controlled human safety dataset for the blend. A 2025 BPC-157 systematic review explicitly found no clinical safety data [8]; 2025-2026 reviews note that unapproved musculoskeletal peptides can carry potential for serious harm and operate largely outside regulatory oversight [9]. Long-term human safety of the combination is unknown. ### Are BPC-157 and TB-500 FDA approved or banned by WADA? Neither is FDA-approved for human use, and the blend has no approved indication [12]. Both are prohibited by WADA — BPC-157 under the S0 non-approved-substances category; TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories. In 2023, FDA placed both in its 503A Category 2 of bulk substances flagged for significant safety risks [11]. ### Is Wolverine legal? Status depends on jurisdiction and context. Neither constituent is an FDA-approved medicine, and both are WADA-prohibited in sport. In the U.S. compounding framework, both are currently 503A Category 2 bulk substances, restricting pharmacy compounding access while that status stands [11] [12]. See the [Wolverine legal status and 503A compounding](/legal-status) page. ### Can you get BPC-157 from a compounding pharmacy? Under current FDA status, routine 503A pharmacy compounding of BPC-157 is restricted: FDA placed it in Category 2, outside the enforcement-discretion policy, effective with the September 29, 2023 list update [11]. BPC-157 is on the PCAC agenda for July 23-24, 2026 as a bulks-list candidate, but that is a scheduled discussion, not a change in current status [13]. ### What is the FDA 503A status of Wolverine? Both components of the Wolverine blend are in FDA's 503A Category 2. FDA placed BPC-157, and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," on its list of bulk substances that may present significant safety risks, effective with the September 29, 2023 update [11]. Neither component nor the blend is an FDA-approved medicine [12]. --- The Wolverine blend read off a drafting table — BPC-157 and TB-500 set down as two dimensioned components, their measured findings inked solid and their unproven joint left dashed, with the FDA and WADA record kept in the title block and nothing here prescribed or sold.